Introduction
Hypoplastic myelodysplastic syndrome (h-MDS) is characterized by decreased marrow cellularity, which could be wrongly categorized as aplastic anemia. 1 Clinically, h-MDS shares similar manifestations with normo-/hypercellular myelodysplastic syndrome (NH-MDS), such as cytopenia, bone marrow dyspoiesis, clonal chromosome changes and the possibility of transformation to acute myeloid leukemia (AML). However, it remains controversial whether h-MDS is a distinct clinicopathologic entity that differs from NH-MDS in terms of pathogenesis, clinical features, classification, patterns of chromosome changes, response to treatment and prognosis. 2 Meanwhile, differences in nature of the disease of myelodysplastic syndrome (MDS) between Western and Eastern people have been previously reported, 3, 4 but little is known about the h-MDS group.
Several hypotheses and models have been proposed for the pathogenesis of MDS, including flawed apoptosis, 5 hypermethylation of tumor suppressor genes such as p15, 6 and SOCS1 (suppressor of cytokine signaling-1), 7 which results in gene silencing, unbalanced differentiation and proliferation of progenitor cells, 8 and dysregulation of immune response. 9 Mutations of a lot of genes including AML1, 10 FLT3 11 and RAS 12, 13 are all introduced into the elaboration of MDS mechanism, but their changes in h-MDS remain elusive. As far as survival is concerned, International Prognostic Scoring System (IPSS) plays a decisive role in the prognosis prediction of patients with MDS, 14 but its applicability to h-MDS is not confirmed.
In this study, we sought to compare the clinical features, chromosomal abnormalities, genetic and epigenetic alterations between h-MDS and NH-MDS in a large cohort of Chinese patients in Taiwan, and to verify the applicability of IPSS in this special entity of MDS.
Materials and methods

Patients
We retrospectively reviewed medical records and bone marrow findings in 189 patients with primary MDS diagnosed at the National Taiwan University Hospital, a tertiary referral hospital, between 1984 and 2002. The diagnosis and classification of MDS were made according to the French-American-British (FAB) criteria. 15 Patients with chronic myelomonocytic leukemia or secondary MDS due to antecedent hematological diseases or drugs were not enrolled into our study. Most patients received supportive treatment only. Twenty-four patients were treated with low-dose cytosine arabinoside, 11 with conventional chemotherapy for AML and 18 received allogeneic hematopoietic stem cell transplantation. For Kaplan-Meier survival analysis, the closure date was 30 November 2006. Patients receiving hematopoietic stem cell transplantation were censored at the time of transplantation. This study was approved by the Institutional Review Board of the National Taiwan University Hospital.
Bone marrow aspiration and biopsy
For the initial diagnosis, all patients received bone marrow aspiration and trephine biopsy. Bone marrow aspirate smears were routinely stained with the modified Wright-Giemsa stain (Liu stain), 16 and biopsy specimens were stained with hematoxylin-eosin after decalcification. Hypoplasia was defined as less than 30% of the cellularity in the bone marrow biopsy specimen. 17, 18 The criteria for dyspoiesis included megaloblastoid changes, irregular-shaped nuclei or karyorrhexis of erythroblasts, micro-megakaryocytes, hypolobated or binucleated megakaryocytes and pseudo-Pelger Huet anomaly or hypogranulation of granulocytes. 19 Any of the aforementioned features should surpass 10% in the same lineage to be considered as the evident dyspoiesis.
Cytogenetics
Chromosome study was performed in 175 of the 189 patients. Bone marrow cells were harvested directly or after 1-3 days of unstimulated culture as described previously. 6 Metaphase chromosomes were banded by trypsin-Giemsa technique and karyotyped according to the International System for Human Cytogenetic Nomenclature.
Mutation analysis
Gene mutation studies were performed in 103 patients (19 h-MDS and 84 NH-MDS) for AML1, RAS and JAK2; 102 patients (19 h-MDS and 83 NH-MDS) for PTPN11 and internal tandem duplication of FLT3 (FLT3-ITD); and 101 patients (18 h-MDS and 83 NH-MDS) for KIT. Mutations of AML1 were detected by genomic DNA PCR and direct sequencing using a previously described method. 20 The primer sets used to amplify exons 3-8 were the same as those designed by Harada et al.
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Abnormal sequencing results were confirmed by at least two repeated analyses. Point mutations at codons 12, 13 (exon 1) and 61 (exon 2) of the N-RAS and K-RAS genes were analyzed by PCR on genomic DNA and direct sequencing. 20 Analysis of FLT3-ITD was performed as in previous studies. 22, 23 Mutations of JAK2 and PTPN11 genes, encoding Janus kinase 2 and Shp2, a non-receptor tyrosine phosphatase, respectively, were analyzed using reported methods. 24 Mutations of KIT were detected by genomic DNA PCR and direct sequencing according to a previously described method. 25 The methylation status of SOCS1 and SHP1 (Src homology domain 2-containing phosphatase-1), both encoding proteins functioning as negative regulators of signal transduction, was analyzed in 89 patients (17 h-MDS and 72 NH-MDS) and 87 patients (17 h-MDS and 70 NH-MDS), respectively, by methylation-specific PCR as previously described. 26, 27 Statistics Mann-Whitney U-test was utilized to compare medians of age and hemogram parameters between h-MDS and NH-MDS Table 1 Comparison of clinical and laboratory features between hypoplastic and normo-/hypercellular MDS Only 172 patients, including 33 patients with hypoplastic-MDS and 139 patients with normo-/hypercellular-MDS, could be evaluated by IPSS.
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patients. Pearson's w 2 test was utilized to detect the difference of gender, FAB classification and IPSS distribution between h-MDS and NH-MDS patients. Fisher's exact test was utilized as required. A Cox proportional hazards model was used for multivariate regression analysis. Kaplan-Meier analysis with log-rank test was performed to evaluate the difference in acute leukemic transformation rate and survival between groups. All statistical analyses were performed by SPSS 13.0 for Windows (Chicago, IL, USA). P-values less than 0.05 are taken as statistically significant.
Results
Clinical and laboratory features
Among 189 MDS patients, 37 (19.6%) patients were diagnosed as having h-MDS. Twenty-nine of them were males and eight were females. Males were predominant both in h-MDS and NH-MDS patients. Median ages of h-MDS and NH-MDS patients were 58 and 55 years, respectively (Table 1) . Compared to NH-MDS patients, peripheral-blood white blood cell count and marrow blast percentage were significantly lower in h-MDS patients (P ¼ 0.012 and 0.016, respectively). There was no significant difference in platelet count and hemoglobin level between h-MDS and NH-MDS patients (Table 1) . Refractory anemia (RA) predominated in h-MDS patients, whereas RA with excess of blast was the most common subtype in NH-MDS patients. The distribution of FAB subtypes in h-MDS was significantly different from that in NH-MDS (P ¼ 0.007) ( Table 1) .
Among 33 h-MDS patients who had cytogenetic analysis, 14 (42.4%) had clonal chromosomal abnormalities, an incidence similar to that of NH-MDS patients (Table 2) (Table 1 ). Four h-MDS patients are not included here for the lack of cytogenetic data. There were more patients of Int-1 risk in h-MDS group than in NH-MDS group (P ¼ 0.015).
Genetic and epigenetic alterations in h-MDS and NH-MDS
The comparison of genetic and epigenetic alterations between h-MDS and NH-MDS is summarized in Table 2 . The patients with h-MDS had lower incidences of RAS and AML1 mutations and SOCS1 and SHP1 hypermethylation than those with NH-MDS (5.3 vs 11.9%, 5.3 vs 14.3%, 29.4 vs 45.8%, 52.9 vs 64.3%, respectively), but the differences were not statistically significant. There was no compelling difference in other genetic or epigenetic alterations between h-MDS and NH-MDS patients.
Survival analysis
On the basis of IPSS, 33 h-MDS patients were separated into the lower-risk group (including 'low' and 'Int-1') and the higher-risk group (including 'Int-2' and 'high'). Noticeably, there was a significant survival difference between these two groups in h-MDS patients (median survival 112 vs 16 months, P ¼ 0.002) (Figure 1a) , as in NH-MDS patients (Figure 1b) .
With a median follow-up duration of 98 months in 187 evaluable patients, the cumulated incidence of acute leukemic transformation at 7 years was 8.1% for h-MDS patients and 28.0% for NH-MDS patients (P ¼ 0.004) (Figure 2) . Furthermore, Number of patients with gene mutation/number studied (%). c Number of patients with gene hypermethylation/number studied (%).
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T-C Huang et al the median overall survival was significantly longer in h-MDS than in NH-MDS patients (58 vs 24 months, P ¼ 0.003) (Figure 3a) . In subgroup analysis, the survival difference between h-MDS and NH-MDS patients remained significant only among the patients categorized as 'low' or 'Int-1' risk (P ¼ 0.01) (Figure 3b ), but not among those with 'Int-2' or 'high' risk (P ¼ 0.405) (Figure 3c) . A Cox regression model was used to find out significant prognostic factors for survival among overall MDS patients.
Variables included were age, gender, bone marrow blast percentage, marrow hypocellularity, FAB classification, acute leukemic transformation, chromosome changes and genetic changes. A multivariate model was derived and the P-value of the Omnibus test of model coefficients was o0.001. Parameters of independent significance for overall survival were age, marrow hypocellularity, RA with excess of blast, RA with excess of blast-T, monosomy 5 or 5q deletion and monosomy 7 or 7q deletion (Table 3) .
Discussion
In our series, 19.6% of MDS patients had h-MDS, a percentage slightly higher than that (8-19%) reported in literature. 2, 17, [28] [29] [30] [31] [32] [33] [34] [35] [36] This could be explained by the exclusion of chronic myelomonocytic leukemia in our series. Chronic myelomonocytic leukemia has been reclassified into the category of myelodysplastic/myeloproliferative diseases in the new WHO (World Health Organization) classification in 2001. 37 Its clinical presentation and prognosis are distinct from MDS. 38 So it is necessary to sequester the influence of chronic myelomonocytic leukemia on the comparison of clinical parameters and prognosis between h-MDS and NH-MDS. According to our result, h-MDS patients had lower initial counts of white blood cells, lower marrow blast percentage and a higher frequency of FAB subtype RA than NH-MDS patients, findings similar to other reports. 2, 17, 32 As for the cytogenetic results, the frequency of clonal chromosomal abnormalities was similar between h-MDS and NH-MDS patients (42.4 vs 47.9%, P ¼ 0.580), and there was no difference in the distribution of single, double and complex aberrations between these two groups of patients. This indirectly helped to exclude the possibility of blurred boundaries between h-MDS and aplastic anemia in our series. However, while 26 (18.3%) out of 142 NH-MDS patients who had cytogenetic study showed À7/7qÀ, none of the 19 h-MDS patients had the same change Among 152 normo-/hypercellular MDS patients, 13 patients could not be classified by IPSS and one patient was lost to follow-up soon after diagnosis was performed. Figure 2 The comparison of acute leukemic transformation rate between hypoplastic myelodysplastic syndrome (MDS) and normo-/ hypercellular MDS. Among total MDS patients except for two patients who was lost to follow-up soon after diagnosis, hypoplastic MDS patients were less prone to acute leukemic transformation than normo-/hypercellular MDS patients (P ¼ 0.004).
Comparison of hypoplastic MDS with normo-/hypercellular MDS T-C Huang et al For comparing and delineating different pathogenesis between h-MDS and NH-MDS, we performed analysis of an array of genetic and epigenetic markers as described above. Although AML1 and RAS mutations and SOCS-1 hypermethylation, all associated with poor survival, 7, 24, 40 occurred more frequently in NH-MDS patients than in h-MDS patients, the difference was not statistically significant, probably due to the limited number of patients studied. We think that more patients are needed to demonstrate the postulated difference.
To identify different survival groups in h-MDS patients, we took advantage of IPSS for risk stratification. Obviously, in our series, h-MDS patients of lower risks (that is, 'low' or 'Int-1') had a significantly longer survival (112 vs 16 months, P ¼ 0.002) than those of higher risks (that is, 'Int-2' or 'high'). To the best of our knowledge, this is the first study to demonstrate that IPSS remains applicable in this distinctive clinical entity.
Our Cox regression model revealed that marrow hypocellularity is an independent parameter of overall survival among all MDS patients. Therefore, the comparison of prognosis between h-MDS and NH-MDS would be reasonable and informative. It was demonstrated that the median survival of h-MDS patients was significantly longer than NH-MDS patients (58 vs 24 months, P ¼ 0.003), particularly among those categorized as lower risks according to IPSS (that is, 'low' or 'Int-1') (112 vs 32 months, P ¼ 0.01). The findings that h-MDS patients had a lower frequency of À7/7qÀ and a trend of lower prevalence of RAS and AML1 mutations and SOCS1 hypermethylation, all associated with poor prognosis, than NH-MDS patients in this study might explain the difference of prognosis between these two groups of patients.
The survival superiority of h-MDS over NH-MDS had been controversial in earlier reports. 2, 17, 32, 39, 41 Herein, we would raise four points to explain this. First, all previous reports about the survival analyses did not stratify h-MDS patients further by IPSS so that the interpretation of analysis results would be interfered. Second, the population number was small and only a few patients had cytogenetic data whereby h-MDS patients Abbreviations: MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess of blast; RAEB-T, RAEB in transformation; À5, monosomy 5; 5qÀ, 5q deletion; À7, monosomy 7; 7qÀ, 7q deletion.
Comparison of hypoplastic MDS with normo-/hypercellular MDS T-C Huang et al could be overlooked for aplastic anemia. Third, secondary MDS often consists of chromosome 7 abnormalities and presents with bone marrow hypocellularity so that it would be categorized into Int-2-or high-risk group in IPSS and is associated with poor prognosis. In our study, we only recruited patients with primary MDS. Finally, we would like to emphasize the pronounced influence of hematopoietic stem cell transplantation on the prognosis of MDS patients. In survival analysis, our patients receiving hematopoietic stem cell transplantation were censored at the time of conditioning, whereas it was not mentioned in prior reports. In summary, hypoplastic MDS is a distinct subgroup of MDS and is characterized by lower white blood cell counts and marrow blast percentage, preponderance of RA and lower incidence of chromosome 7 abnormalities. There was a trend of lower incidence of RAS and AML1 mutations and SOCS-1 hypermethylation in h-MDS patients. We propose that IPSS can be applied to the prognostic prediction of h-MDS patients. Hypocellularity of the bone marrow is a crucial prognostic factor for MDS patients, especially in the risk groups of 'low' and 'Int-1.'
